Graphical Abstract Highlights d The crystal structure of Mycobacterium smegmatis MmpL3 has been determined d Two Asp-Tyr pairs in the TM region of MmpL3 facilitate proton-translocation d SQ109, an anti-TB drug, binds inside the protontranslocation channel of MmpL3 d Rimonabant, an antagonist for the cannabinoid receptor CB 1 , also inhibits MmpL3
In Brief
MmpL3 has emerged as an important target for anti-tuberculosis drug discovery with inhibitors of this protein currently in clinical trials. Here, crystal structures of mycobacterial MmpL3 alone and in complex with four TB drug candidates have been determined. These data pave the way for the rational development of MmpL3 inhibitors as potent TB drugs.
INTRODUCTION
Mycobacteria cause a number of serious diseases in humans, including tuberculosis (TB), leprosy, Buruli ulcer, and pulmonary nontuberculous mycobacterial disease (Forbes et al., 2018) . In 2017 alone, there were an estimated 10 million new cases of TB and 1.3 million deaths, making it the leading cause of human fatality due to infectious disease (World Health Organization, 2018) . Furthermore, the emergence of multi-drug-resistant, extensively drug-resistant, and totally drug-resistant TB makes the disease exceptionally difficult to treat (Gandhi et al., 2010; Udwadia et al., 2012) . Thus, there is an urgent need to develop new therapeutic drugs to target TB and the other diseases described above.
Mycobacterial genomes encode for a set of membrane proteins identified as MmpL (Mycobacterial membrane protein Large), which belong to the Resistance, Nodulation and Division (RND) protein superfamily . The RND family of transporters are ubiquitous among bacteria, archaea, and eukaryotes. Their activity is driven by the proton motive force (PMF) (Nikaido, 2018) . In Gram-negative bacteria, RND transporters (and MmpL proteins) include efflux pumps to actively extrude many antibiotics, and therefore play an important role in drug resistance (Blair et al., 2014; Viljoen et al., 2017) . The Mycobacterium tuberculosis (M. tuberculosis, Mtb) genome encodes 13 MmpL proteins (Cole et al., 1998; Domenech et al., 2005) . MmpL3, 4, 5, 7, 8, 10, and 11 have been reported to participate in the biosynthesis of the complex cell envelope of mycobacteria (Szé kely and Cole, 2016) . MmpL5 and MmpL7 can actively efflux anti-tubercular drugs, including the recently approved drug bedaquiline (Hartkoorn et al., 2014; Rodrigues et al., 2012) .
MmpL3 is the only MmpL deemed essential for the replication and viability of bacterial cells (including Mtb) (Domenech et al., 2005; Grzegorzewicz et al., 2012) . Indeed, downregulation of MmpL3 expression prevents cell division and leads to rapid cell death (Degiacomi et al., 2017; Li et al., 2016a) . The sequence of MmpL3 is highly conserved across mycobacteria and corynebacteria ( Figure S1A) where it participates in the transport of mycolic acids (Varela et al., 2012) . Mycolic acids are key components of the outer membrane and essential for mycobacterial growth, rendering the bilayer extremely hydrophobic and impermeable to exogenous compounds, including many antibiotics (Brennan and Nikaido, 1995; Nataraj et al., 2015) . Specifically, MmpL3 is responsible for the translocation of mycolic acids in the form of trehalose monomycolate (TMM) from their production site in the cytoplasm to the cell envelope (Grzegorzewicz et al., 2012) . Subsequently in the periplasmic space, a mycolate chain from one TMM molecule is transferred to another to form trehalose dimycolate (TDM; cord factor), or to arabinogalactan yielding wall-bound mycolates (Jankute et al., 2015; Takayama et al., 2005) . The arabinogalactan-bound mycolates make up the thick, waxy, and difficult-to-permeate outer coating of the bacterial envelope, which is essential for mycobacterial growth (Brennan and Nikaido, 1995) . Hence, inactivation of the MmpL3 transporter inhibits the pivotal step of the synthetic pathway of the mycolic acids in mycobacteria. Thus, it is an excellent target for the discovery of anti-tubercular drugs (Jackson et al., 2013; North et al., 2014) .
Several compounds, including diamines (Sacksteder et al., 2012; Tahlan et al., 2012) , indolcarboxamides (Manjunatha and Smith, 2015; Rao et al., 2013; Stec et al., 2016) , diphenyl pyrroles (La Rosa et al., 2012) , adamantyl ureas (Grzegorzewicz et al., 2012) , and spirocycles (Ballell et al., 2013) have been developed as MmpL3 inhibitors. Most notably, the diamine, SQ109, has shown promise in a Phase 2b-3 clinical study as an anti-TB agent (World Health Organization, 2018) . It has excellent activity against all forms of Mtb, including drug-resistant clinical strains (Sacksteder et al., 2012) . The in vitro bacterial mutation rate for SQ109 is very low, which suggests the development of resistance to this compound could be slow (Sacksteder et al., 2012) . In addition, the application of SQ109 in combination with other drugs can have synergistic effects in cell-based assays (Chen et al., 2006; Reddy et al., 2010) . That MmpL3 inhibitors are now entering clinical trials demonstrates the importance of this protein as a target for developing new TB therapies. To date, there is limited structural information for the entire MmpL family. This is highlighted by the fact that, the only structure determined for an MmpL component is for the PC subdomain (D2), an 88-residue periplasmic fragment from the ectodomain of MmpL11 (Chim et al., 2015) . Thus, structural data for any intact MmpL has remained elusive.
In order to address this deficiency, we have determined the X-ray crystal structures of Mycobacterium smegmatis (M. smegmatis) MmpL3 alone and in complex with four drug candidates. The MmpL3 from this organism serves as an excellent model for the Mtb counterpart. This data will greatly facilitate the development of MmpL3 inhibitors as anti-TB therapeutic drugs.
RESULTS

Determination of the MmpL3 Structure
Of the MmpL proteins encoded by mycobacterial genomes (Figure S1A) , mmpL3 and mmpL11 are the only mmpL genes conserved across mycobacteria . The importance of mmpL3 is illustrated by the fact that it is the only mmpL gene that cannot be successfully knocked out in Mtb (Domenech et al., 2005) . That Mtb mmpL3 could rescue the viability of the M. smegmatis mmpL3 knockout mutant further indicates that these mmpL3 orthologs have highly conserved functions (Grzegorzewicz et al., 2012) . Therefore, M. smegmatis MmpL3 is a reasonable model for the Mtb counterpart. A construct consisting of the full-length M. smegmatis MmpL3 was amenable to expression and purification. However, this sample was susceptible to rapid degradation ( Figure S1C ), possibly due to instability of the cytoplasmic C-terminal domain (CTD) ( Figure S1B ). This domain is predicted to have little secondary structure and a sequence that is poorly conserved within the MmpL3 family (Figure S5A) , making its characterization challenging. The function of this domain remains the subject of conjecture but is proposed to mediate subcellular localization of MmpL3 (Carel et al., 2014) . More importantly, this domain appears non-essential to the activity of the transporter itself or in cell growth and division (Belardinelli et al., 2016) . To solve the problem of degradation, a recombinant MmpL3 construct consisting of the first 748 residues with T4 lysozyme fused to its C-terminus was expressed, purified, and crystallized, with its crystal structure determined at 2.7 Å resolution (Table S1 ).
Overall Architecture of MmpL3
MmpL3 with a fused T4 lysozyme is monomeric in the crystalline state. However, this contrasts with AcrB (Murakami et al., 2002) , a classic RND superfamily member involved in bacterial multidrug resistance, and CmpL1 (a homolog from Corynebacterium glutamicum) (Belardinelli et al., 2016) , both of which have been reported as trimers, while another RND family member, NPC1, is a monomer (Gong et al., 2016) and HpnN is a dimer (Kumar et al., 2017) . To determine the quaternary structure of MmpL3 in the absence of T4 lysozyme, full-length MmpL3 was expressed and purified ( Figure S1D ). The SAXS analysis of this construct gave a molecular weight in the 140-190 kDa range (Table S2 ). In consideration of the presence of detergents, the SAXS data are suggestive that the full-length protein is most likely monomeric. In addition, BN-PAGE analysis ( Figure S1E ) also indicates that MmpL3 is a monomer. Nonetheless, given the diversity of quaternary structures for this family of proteins, we cannot rule out the possibility that MmpL3 could form a higher oligomeric structure, especially when it is located within the inner membrane of the mycobacterial cell.
MmpL3 appears to have been formed by a gene duplication event, where the two halves of the molecule comprising a periplasmic headpiece (the N-/C-terminal pore subdomain, PN/PC for short) and a transmembrane domain (the N-/C-terminal transmembrane subdomain, TMN/TMC for short) combine to form a molecule with overall dimensions of 93 3 55 3 25 Å and with approximate 2-fold symmetry (Figures 1A, S1G and S1H). It was previously suggested that internal gene duplication and gene splitting events occurred in order to acquire a suitable symmetry for the protein to carry out its function (Sandhu and Akhter, 2015) . Sequence comparison of the two halves shows that they have 19.2% identity and 40.0% similarity ( Figure S5C ). In total, 293 Cas from the two halves of MmpL3 can be superimposed with an RMSD of 2.78 Å ( Figure S1H ), wherein TMN can be overlaid onto TMC with an RMSD of 2.57 Å (197 Cas aligned) and PN can be overlaid onto PC with an RMSD of 3.30 Å (105 Cas aligned). This level of structural similarity is consistent with the occurrence of a gene duplication event.
Pore Domain Structure
The periplasmic pore domain is composed of two subdomains, PN and PC (Figures 1A and S1I), both of which adopt a b-a-b-a-b fold (Figures S1G and S1I), as is also observed in the D2 domain (PC) of MmpL11 (Chim et al., 2015) and the pore subdomains (PN1, PN2, PC1, and PC2) of AcrB (Murakami et al., 2002) ( Figure S1K ). The subdomains intertwine to create a central cavity, which connects to three openings, a funnel at the top (G T ), an opening in the front (G F ) , and an opening at the back (G B ) of the headpiece ( Figure 1A ). These openings are gated by hydrophilic residues (Figures S1I and S1J), which could allow specific molecules to enter or exit. Interestingly, two 6-n-dodecyl-a, a-trehalose (6-DDTre) detergent molecules, which are mimics for the substrate TMM ( Figure S2A ), are bound in the cavity and G T ( Figures 1A and S2D ). Notably, the trehalose head of one 6-DDTre is stabilized near G F by hydrogen-bonding with the side chains of hydrophilic residues Asp58, Arg63, Asp144 and the main chain of Asp64 and hydrophobic interactions with the residues of Tyr44, Ser54 and Leu55 ( Figure S2B ). The alkyl tail of the detergent leans against transmembrane helix II (TMH II) and inserts into the hydrophobic pocket surrounded by eight amino acid side-chains ( Figure S2B ). In G T , the trehalose head of 6-DDTre is partially exposed to the solvent ( Figure S2D ). Its tail is surrounded by 12 residues ( Figure S2C ). Since both 6-DDTre and TMM share the same trehalose head, this suggests potential roles for these openings in TMM transportation.
Transmembrane Region of MmpL3
The transmembrane region contains 12 transmembrane a helices (TMHs) (Figures 1A and S1G) with a pseudo-two-fold symmetry axis relating the six N-terminal helices and the six C-terminal helices (RMSD for 197 superimposed Cas is 2.57 Å ) (Figure 1B) . The transmembrane region also contains two extra a helices (aIs) attached to the cytoplasmic membrane surface, located at the N terminus (aI1), and between TMH VI and TMH VII (aI2) ( Figure S1G ). TMH IV and TMH X form the core of the transmembrane helix bundle ( Figure 1B ). In the middle of these two helices, there are two pairs of hydrophilic residues (Asp256-Tyr646 and Asp645-Tyr257), which link the two helices due to their side chains that form hydrogen bonds ( Figures 1B and 1C ). The Asp-Tyr pairs are a conserved feature of MmpL family transporters except for MmpL7 . They are similarly located as the Asp-Asp-Lys triad in AcrB and Asp-Asp-Thr triad in SecDF ( Figures S3A-S3C ), both of which are known to be involved in a proton relay pathway (Eicher et al., 2014; Murakami et al., 2006; Tsukazaki et al., 2011) . Significantly, mutation of the Asp-Tyr pairs in MmpL3 abrogates the growth of mycobacteria in culture , consistent with them playing an important role in proton translocation, not only in MmpL3, but more broadly across the MmpL family.
SQ109 Interactions in MmpL3 Binding Pocket
Although several anti-mycobacterial inhibitors have been suggested to target MmpL3 (Poce et al., 2016) , there has been a lack of experimental evidence to show a direct interaction with MmpL3. SQ109 is a promising new anti-TB drug in development, and has been subjected to a Phase 2b-3 clinical study (World Health Organization, 2018). It has been suggested to act by inhibiting MmpL3 of Mtb (Tahlan et al., 2012) , but is yet to be verified by direct experimental evidence. SQ109 also has activity against Helicobacter pylori and the fungi, Candida albicans, suggesting that it could be active on multiple targets, since these pathogens do not contain a similar gene (Li et al., 2014a; Li et al., 2014b) . To verify whether mycobacterial MmpL3 is a direct target for SQ109, we used a microscale thermophoresis (MST) assay, which shows that SQ109 binds to M. smegmatis MmpL3 with a dissociation constant (K d ) of 1.65 mM (Figure 2A ). In cell-based inhibition assays, the growth of M. smegmatis is susceptible to the exposure of SQ109 in a dose dependent manner ( Figure 2F ). The inhibitory effect could be partially reversed in the M. smegmatis strain overexpressing an introduced mmpl3 gene on a plasmid. These data support that MmpL3 is a direct target for SQ109. In order to elucidate the interactions between SQ109 and MmpL3, we determined the structure of the complex at 2.6 Å resolution (Table S1 ). Unambiguous tadpole-shaped density at the center of TM domain (Figures 3A and 3B and S4A) showed that SQ109 is bound to this region in an extended conformation. Superimposition of the apo and complex structures gives an RMSD of 1.18 Å for 707 aligned Cas with the largest differences located in the TM domain (Figure 3A) . Upon inhibitor binding, most of the six C-terminal transmembrane helices undergo noticeable conformational changes and move away from the center of the TM region ( Figure 3A) , expanding the narrow proton-translocating channel to accommodate SQ109. These conformational changes produce a pocket with a volume of $282 Å 3 in the proton flow passage ( Figure 3C ), matching the size and shape of the lead compound. Figure S7 and Table S5. SQ109 is deeply embedded in the center of TMH bundle, surrounded by TMH IV, V, VI, X, XI, and XII ( Figure 3A ). The interface between SQ109 and MmpL3 can be roughly divided into four layers ( Figure 4A and Table S3 ). The geranyl tail makes favorable interactions with a hydrophobic subsite composed of two layers (layer 1 and layer 2) ( Figure 4A ). Ile249, Ile319, Ala637, Val638, and Ser301 form layer 1, while Ile253, Ile297, Gly641, Leu642, and Leu686 form layer 2 ( Figures 4A and 4C ) while the geranyl tail leans against the groove between TMH V and TMH X (Figure 4B) . In comparison with the apo-structure, Leu642 moves $3.1 Å away from the center of the TM region to make room for the methyl group which protrudes out from the backbone of SQ109 ( Figure 4D ). In layer 3, it is noteworthy that Asp645, a component of the Asp-Tyr pair in the apo-structure, re-orientates to interact with the amino groups of SQ109 (Figures 4A and 4D  and Table S3 ). Meanwhile, the hydroxyl group of Ser293 rotates to form hydrogen bonding interactions with Asp645 and Tyr257 ( Figures 4A and 4D ). On the other hand, the hydrogen bond between Tyr646 and Asp256 is broken due to the movement of TMH X ( Figures 3B and 4D ). Thus, both of the two Asp-Tyr pairs, which likely play pivotal roles in proton-translocation, are disrupted upon SQ109 binding. Phe260 and Phe649 comprise layer 4 and the side-chains of both of these undergo dramatic conformational changes upon SQ109 binding, with tips of their phenyl rings rotated by as much as 7 Å to form a ''V''-shaped structure, thereby holding the adamantine group as a base (Figures 4A and 4D) . In short, SQ109 inhibits MmpL3 by occupying the protontransportation channel, disrupting the Asp-Tyr pairs implicated in proton relay and thus blocking the proton motive force for substrate translocation. The residues which constitute the binding pocket for SQ109 in MmpL3, are well conserved across mycobacteria (Figures 4C, S5A and S5B), implying that SQ109 may have broad-spectrum anti-infective activity against multiple species of mycobacteria. This idea is supported by previous reports that SQ109 is active against both Mtb and M. smegmatis Dashed red circles mark the space created between TM helices IV and X. See also Figure S4 and Table S1. with MICs of 0.3-0.6 mM and 9.6 mM (Li et al., 2014a) , respectively.
AU1235 Binding Mode of MmpL3
AU1235, an adamantyl urea compound that shows good bactericidal activity against both Mtb (MIC = 0.6 mM) and M. smegmatis (MIC = 9.8 mM), has also been reported to target MmpL3 (Grzegorzewicz et al., 2012). The K d of AU1235 for MmpL3 is 0.29 mM (Figure 2B) , 5.7-fold lower than that for SQ109. We have also determined the structure of MmpL3 in complex with this compound (Table S1 ), which shows that AU1235 binds in the same pocket as SQ109 ( Figures 5A and S4B ). Furthermore, the binding mode of AU1235 is similar to that of SQ109 (Figures 5B and  5C and 5F and Table S3 ). The difference in binding is due to the bulky tri-fluorophenyl group in AU1235 generating more hydrophobic interactions than does the geranyl tail of SQ109 (Figure 5F) . Upon binding, AU1235 induces very similar conformational changes in MmpL3 to those seen for SQ109 (Figures 5A and 5F) . As a consequence, AU1235 also disrupts the two Asp-Tyr pairs for proton relay, and thus also blocks the proton motive force for substrate translocation.
ICA Binding Mode of MmpL3
Indolcarboxamides (ICAs) have been reported as a new class of anti-tuberculosis agent (Manjunatha and Smith, 2015; Rao et al., 2013) . Genetic and lipid profiling studies also identified the molecular target of this group of compounds as MmpL3 (Rao et al., 2013) . ICA38 has the highest in vitro anti-Mtb activity in this group with MIC values as low as 0.003 mM (Stec et al., 2016) . Although this compound was not pursued for further studies due to poor bioavailability, its derivatives, NITD-304 and NITD-349 (Novartis), have proven to be good preclinical candidates for further development to treat multidrug-resistant TB (Manjunatha and Smith, 2015; Rao et al., 2013) . ICA38 itself, binds to MmpL3 with a K d of 0.16 mM ( Figure 2C ). The structure of MmpL3 in complex with ICA38 was determined at 2.8 Å (Table  S1 ) and shows that ICA38 has a similar binding mode as SQ109 and AU1235 ( Figure 5A ). It recognizes the same binding pocket as SQ109 and AU1235 and is in an extended conformation (Figures 5D-5F and S4C). Compared with the other two compounds, the bulky indole group fits snugly into the hydrophobic subsite on the top of the channel, producing a larger hydrophobic interaction than both the geranyl tail of SQ109 and the fluorophenyl group of AU1235 ( Figures 5D and 5F ). Again, binding of this inhibitor disrupts the two Asp-Tyr pairs participating in proton translocation. Meanwhile, the amide group of ICA38 hydrogen bonds to the side chain of Asp645 and the carbonyl oxygen of ICA38 accepts a non-canonical hydrogen bond from the side chain of Tyr646 ( Figures 5D and 5E and Table S3 ). The carbocyclic spiro group favorably inserts into the bulky hydrophobic subsite at the bottom of the tunnel, thus producing a more extensive set of hydrophobic interactions compared with the adamantine group in SQ109 and AU1235 ( Figures 5D and 5F ).
Rimonabant, a CB 1 Antagonist, Also Targets MmpL3
As MmpL3 is a promising new drug target for Mtb infection, we initiated a program to discover inhibitors of MmpL3 by virtual screening using our structural data. To our surprise, rimonabant, a CB 1 antagonist (Rinaldi-Carmona et al., 1994) , appeared to be a good fit to the same binding pocket of SQ109 and AU1235. This result is supported by a previous study (Ramesh et al., 2016) , which found that rimonabant could inhibit the growth of Mtb with an MIC of 54 mM, although there was no evidence that this compound directly targeted MmpL3. Our MST assay showed that rimonabant does indeed bind MmpL3, with a K d value of 29 mM ( Figure 2D ). The cell-based inhibition assay showed that the inhibitory effect could be partially reversed in the M. smegmatis strain containing the introduced overexpressing mmpl3 gene on a plasmid ( Figure 2F ). These data support that MmpL3 is the direct target of rimonabant. Since rimonabant has been approved by the European Medical Agency as an adjunct to diet and exercise for treating obesity (Janero and Makriyannis, 2009) , it is a promising starting point for the development of anti-mycobacterial compounds with improved efficacy.
The structure of MmpL3 in complex with rimonabant shows that rimonabant also binds at the heart of the MmpL3 TM domain (Figures 6A and 6B and S4D and Table S1 ). Due to the intrinsic differences in the carbon skeleton, the binding mode differs from that seen for SQ109, AU1235, and ICA38 ( Figure 6A ). Upon binding, TMH IV 244-254 undergoes a marked flexing, so that it moves away from the center of the TMH bundle in the region adjacent to the bound rimonabant ( Figure 6A , in small circle). In contrast, the shifts in TMH VII-XII are smaller than seen upon binding of SQ109, AU1235, and ICA38 ( Figure 6A , in large circle). The net result is to form a pocket with a volume of $305 Å 3 , which accommodates rimonabant. To facilitate the explanation of the binding mode of rimonabant, we term the 2, 4-dichlorophenyl ring as ''Arm 1,'' the 4-chlorophenyl ring as ''Arm 2,'' and the piperidinyl-1-carbamoyl as ''Arm3'' ( Figure 6D ). The pyrazole ring core (including the 4-methyl group) inserts at the center of the TMH bundle, perpendicular to the membrane and interacts with hydrophobic residues Gly641, Leu642, and Ile253 ( Figures  6C and 6D) . Arm 1 occupies a hydrophobic pocket surrounded by five aliphatic amino acid side-chains ( Figures 6C and 6D) . Arm 2, which has a different orientation to the geranyl tail of SQ109, protrudes into a neighboring hydrophobic subsite formed by the side chains from Val245, Ile319, Val638, and Leu708 ( Figures 6A, 6C and 6D ). The bulky Arm 3 thrusts into the heart of the two Asp-Tyr pairs and breaks the hydrogen bonds connecting them by forming polar interactions with Asp645 ( Figures 6C and 6D and Table S3 ). Phe260 remains almost undisturbed while the phenyl ring of Phe649 rotates downward to face the aromatic ring of Phe260, thus forming p-p interactions (Figures 6C and 6E) . Rimonabant binds to mycobacterial MmpL3 in a manner distinct from its interactions with human CB 1 receptor (Figures S3D-S3G ). Rimonabant and other ligands in its class target the CB 1 receptor at the interface between the extracellular region and the TM domain ( Figure S3E ). Since there is no available structure for rimonabant bound to CB 1, the structure of CB 1 in complex with AM6538 (Hua et al., 2016) , a rimonabant analog, was compared with that of MmpL3-rimonabant, confirming that this class of compounds targets entirely different regions in MmpL3 and CB 1 ( Figures  S3E-S3G) .
A Chimeric MmpL3 for Inhibitor Screening
In total, there are 23 amino acid side-chains that bind to the four different inhibitors ( Figures S5A and S5B ). Comparing the inhibitor binding sites for M. smegmatis and Mtb MmpL3, there are only four differences ( Figure S5A ). These are Ser301, Ile319, Val638, and Leu686, which are changed to alanine, threonine, leucine, and valine, respectively. In order to study the interaction between the inhibitor and the ortholog from Mtb, we made an M. smegmatis version of MmpL3 whose residues in the inhibitor binding pocket are replaced by the equivalent residues in Mtb. The MST assays show that this chimeric MmpL3 (S301A/I319T/V638L/L686V) binds to SQ109, AU1235, ICA38, and rimonabant, with K d values of 1.8 mM, 0.2 mM, 0.11 mM and 41.4 mM, respectively (Figures 2A-2D) , which are very similar to those for wild-type M. smegmatis MmpL3. M. smegmatis MmpL3 therefore represents an excellent mimic for the Mtb protein and this chimeric MmpL3 can be used for future drug screening.
Potential Effects of Drug-Resistant Mutations on Inhibitor Binding
As MmpL3 is well conserved among mycobacteria , the resistance mutation data (Table S5) can be mapped onto the structure of MmpL3. Approximately 80% of mutations lie inside or within 10 Å of the SQ109-AU1235-ICA38-rimonabant combined binding pocket ( Figures S7A-S7C) . These mutation data confirm that the MmpL3 proton-translocating channel is the common target for these compounds and further emphasizes the significance of this channel as a hotspot for the binding of drug candidates. The remaining 20% of mutations are located in PN/PC domains, TMH1, 3, 7, 9, the TM6-7 loop and CTD, the latter of which is not visible in our model ( Figures S7A and S7C) .
In order to investigate the potential effects that the resistance mutations have on inhibitor binding, we mapped 13 mutation sites reported for SQ109, AU1235 and ICA38 derivatives onto our structural model ( Figure 2E and Table S5 ) and were able to express, purify and characterize twelve of these. Among these, Y257C is a resistance mutation when exposed to both SQ109 and AU1235. The MST data show that these compounds bind only very weakly to the mutant protein (Figures 2A and 2B) . This is because Tyr257 plays an important role in stabilizing the hydrophilic S4 subsite and enhancing hydrophobic interactions with these inhibitors in the S5 subsite ( Figures 7B and  7C) . Similarly, mutation of Ser293 to alanine severely disrupts binding of SQ109 and AU1235 (Figures 2A and 2B) . It is noteworthy that even replacement of serine to threonine can have a marked impact on binding affinity. S293T only weakly binds to both SQ109 and ICA38 while the K d value for AU1235 increases 6.6-fold compared with the wild-type protein (Figures 2A-2C ). In addition, mutation of Ile297 to phenylalanine severely affects the binding of SQ109 and AU1235 (Figures 2A and 2B ). The reason for this is that Ile297 is located in the S3 subsite and the change to a bulky hydrophobic side chain causes steric hindrance (Figures 7B and 7C) . The T316I and S596I mutants bind to ICA38 more weakly than the wild-type protein ( Figure 2C ). However, it is not obvious from our structures why this is the case. The side chain of Thr316 interacts with the carbonyl oxygen of Leu312 to stabilize TMH VI ( Figure S7D ), which is involved in S3 subsite formation ( Figure 7D ). Ser596 is very close to the side chain of Trp640 on TMH X ( Figure S7D ), which plays an important role in binding pocket formation. Thus, the change to a large aliphatic side chain may result in movement of TMH X, thus affecting inhibitor binding. This suggests that mutations close to or within this binding pocket can have a significant effect on drug binding. For the Q40R, I194R, I572P, and A705T mutations which are remote from this binding pocket, their K d values do not change significantly (Figures 2A and 2C) . It therefore remains unclear as to how these mutations confer drug resistance.
A rational approach to design next generation of MmpL3 inhibitors with improved resistance profiles could thus be achieved by avoiding direct contacts with these residues that can mutate to confer drug resistance. Another strategy is to incorporate conformational flexibility in the drugs (e.g., more freely rotatable bonds). This can allow the drugs to adapt to structural changes in the inhibitor binding pocket due to mutation.
DISCUSSION
MmpL3 is an inner membrane protein, which plays a crucial role in transport of TMM for the synthesis of mycolic acids, which are essential for the viability of mycobacterial cells. However, its exact function has not been elucidated. Our MmpL3 crystal structure provides a basis for considering the molecular mechanism of TMM export. Two putative pathways for substrate entry into MmpL3 are shown in Figure S2D . It is suggested that substrates located in the inner leaflet of the membrane can be transported across the membrane through the transmembrane groove at the periphery of transmembrane domain (Kumar et al., 2017; Li et al., 2016b; Oswald et al., 2016) , wherein MmpL3 acts as flippase (Xu et al., 2017) . Alternatively, TMM located in the outer leaflet of the membrane could gain access to G F that opens into the periplasm, which is gated by hydrophilic residues to recognize the trehalose head of TMM. G T is one possible exit for TMM since this opening does not appear to form strong interactions with the trehalose head, making it convenient for substrate release. Whether flipping and release is coupled or not remains unclear. In any case, these events are driven by the proton motive force and the Asp-Tyr pairs are a feature for the proton-translocating pathway of MmpL3.
Targeting the mycolic acid synthesis pathway has, for more than 50 years, been an attractive approach for the development of antibiotics for TB therapy (North et al., 2014) . Isoniazid (INH), which inhibits mycolic acid synthesis, remains as the most Figure S6 and Table S4. important first-line anti-TB drug since 1952 (Bernstein et al., 1952) . However, resistance occurs frequently because the prodrug (INH) needs to be transformed to its active counterpart (isonicotinic acyl radical) by the enzyme catalase-peroxidase (KatG), which is a non-essential enzyme and loss-of-function mutations often arise in the katG gene (Heym et al., 1995; Jenkins et al., 2011; Zhang et al., 1992) . Therefore, a drug lead other than a prodrug, which can directly inhibit the pivotal target appears to be a better option. Development of inhibitors directly targeting the essential protein, MmpL3, is a highly attractive alternative. This proposition is supported by data that show the in vitro bacterial mutation rate for SQ109 is very low (>10 À11 ) (Sacksteder et al., 2012) .
To date, many chemical scaffolds, such as diamines, adamantyl ureas, indolcarboxamides, diphenyl pyrroles, and spirocycles have been reported to inhibit the growth of mycobacteria and to target MmpL3 (Poce et al., 2016) . The diamines and indolcarboxamides have already entered clinical trials or preclinical studies (Rao et al., 2013; World Health Organization, 2018) . The current literature suggest they all target MmpL3 since the resistant mutations have been specifically mapped to the mmpL3 gene Grzegorzewicz et al., 2012; Ioerger et al., 2013; Kozikowski et al., 2017; La Rosa et al., 2012; Lun et al., 2013; McNeil et al., 2017; Rao et al., 2013; Rayasam, 2014; Stanley et al., 2012; Tahlan et al., 2012; Trofimov et al., 2018; Zheng et al., 2018) . Since our structural data are only for four MmpL3 inhibitors, we investigated if molecular docking could indicate how six other putative MmpL3 inhibitors might bind to this protein. In all cases reasonable docking poses were found to show that they can fit inside the proton-translocating channel ( Figures S6 and S7 ; Table S4 ).
An overlay of the structures of the four complexes revealed that the inhibitor binding pocket can be divided into five subsites (S1-S5) ( Figure 7A ). Except for the S4 subsite, S1, S2, S3, and S5 are all hydrophobic. S1 and S2 are comparatively smaller, while S3 and S5 are both bulky enough to accommodate large hydrophobic groups to enhance binding ( Figure 7A ). The two Asp-Tyr pairs are the key components of the S4 subsite ( Figure 7A ). These structures have elaborated a common inhibitory mechanism. Upon binding, each of the four drug candidates occupy 3-5 subsites in the proton-translocating channel ( Figures 7B-7E) , disrupt the two Asp-Tyr pairs for proton relay, and in so doing block the proton motive force for substrate translocation. The detailed structural information for the binding pocket revealed here represents a major advance for the design of potent inhibitors that target MmpL3. Importantly, our structural data and the relatively modest K d values (high nM to low mM range) for the active compounds with MmpL3 show that there is great scope to rationally optimize these leads into highly potent anti-TB drugs.
Here, we provide the apo-structure of MmpL3, which can serve as a framework for understanding the function of this and other MmpL family members. More generally, this report describes structures of drug candidates which can block the proton motive force to inhibit an RND family member, many of which are important targets for anti-bacterial drug discovery. These data will therefore provide inspiration for the design of new classes of antibiotics. It is remarkable that rimonabant adopts completely different binding modes to inhibit mycobacterial MmpL3 and human CB 1 receptor. Thus, developing rimonabant analogs that are specific for mycobacteria should be entirely feasible. Since MmpL3 and its orthologs are well conserved across mycobacteria and corynebacteria, these results may facilitate the development of drugs which are broadly effective against these and other human pathogenic infectious diseases including TB, leprosy and diphtheria.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Expression plasmids contain mmpL3 gene (MSMEG_0250) from M. smegmatis strain mc 2 155 genomic DNA. Recombinant MmpL3 proteins were overexpressed in M. smegmatis mc 2 155 cells in Luria broth (LB) liquid media (Expression systems). Cells were grown at 37 C at 220 rpm until the OD 600 reached 1.0$1.2. Addition of acetamide to a final concentration of 0.2% (w/v) initiated induction. Cells were then grown for four days at 16 C.
METHOD DETAILS
Cloning and expression of MmpL3
The mmpL3 gene (MSMEG_0250) was amplified from M. smegmatis strain mc 2 155 genomic DNA by PCR using Phanta Max DNA polymerase (Vazyme). The DNA sequence (2,244 bp) coding the N-terminal 748 residues was sub-cloned into pM261 vector, under the control of an acetamide promoter. T4 lysozyme (160 aa), followed by a C-terminal 10 3 His tag, was fused to the truncated C-terminus of MmpL3. The resultant plasmid was transformed into M. smegmatis mc 2 155 cells by electroporation. The cells were cultivated in Luria broth (LB) liquid media supplemented with 50 mg mL -1 kanamycin and 20 mg mL -1 carbenicillin. When the cells were grown to an optical density (OD 600 ) of 1.0$1.2 at 37 C, overexpression of the recombinant protein was induced by 0.2% (w/v) acetamide at 16 C. After four days, cells were harvested by centrifugation and frozen at À80 C. All mutants were overexpressed using the same protocol as the wild-type protein.
Purification of membrane protein MmpL3
Cell pellets were thawed and resuspended in buffer A containing 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 10% (v/v) glycerol, and then lysed by passing through a French Press at 1,200 bar. Cell debris was removed by centrifugation at 8,000 rpm for 15 min at 4 C. The supernatant was collected and ultra-centrifuged at 150,000 g for 1 h. The membrane fraction was resuspended in buffer A and incubated for 1. The eluted sample was concentrated and then applied to a size exclusion chromatography column (Superose-6 increase, GE Healthcare) pre-equilibrated with 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10% (v/v) glycerol and 0.02% (w/v) DDM. The peak fractions were pooled and concentrated to approximately 15 mg mL -1 for crystallization using a 100 kDa cut-off spin concentrator (Millipore). The detergent 6-n-dodecyl-a, a-trehalose (6-DDTre; Anatrace), instead of DDM, was also used for protein purification in the same procedure. All mutants were purified following a similar protocol to the wild-type.
Crystallization
Crystallization trials were performed by the hanging-drop vapor diffusion method at 16 C. The protein solution, diluted to 8$10 mg mL -1 , was mixed in a 1:1 (v/v) ratio with the reservoir solution. Crystals were grown from 10%-20% (v/v) polyethylene glycol monomethyl ether 350 (PEGMME 350), 50 mM ADA (N-(2-Acetamido) iminodiacetic acid) (pH 6.0-7.0) and 7.5%-17.5% (v/v) polyethylene glycol 2000 (PEG2000). Inhibitor-bound crystals were obtained in the same condition by co-crystallization in the presence of either 0.25 mM SQ109 (Sigma), 0.25 mM AU1235 (Efebio), 0.25 mM ICA38 (AppTec) or 0.5 mM rimonabant (MedchemExpress). After optimization, crystals were harvested using 25% (v/v) glycerol as cryo-protectant, flash-cooled and stored in liquid nitrogen for data collection. To obtain Hg-derivative crystals for phasing, crystals were soaked for 30 min in cryoprotectant containing 1 mM K 2 HgI 4 .
Data collection and structure determination X-ray data were collected on beamlines BL17U1, BL18U1 and BL19U1 at the Shanghai Synchrotron Radiation Facility (SSRF), and on beamline I04-1 at Diamond light source and BL41XU at Spring 8. The Hg-derivative dataset was collected at a wavelength of 0.97915 Å . Datasets were processed and scaled using XDS (Kabsch, 2010) and the CCP4 suite (Collaborative Computational Project, Number 4, 1994) . Two Hg atoms were found by the program SHELXD (Sheldrick, 2010) . The initial phases were determined by the AutoSol program in PHENIX (Adams et al., 2002) using the single anomalous diffraction (SAD) method. The fused lysozyme was fitted into the initial density using a model of T4 lysozyme (PDB code: 1CU2) (Gassner et al., 1999) by the ''MR Using Phases'' method in the Molrep program in the CCP4 (Vagin and Teplyakov, 1997) . The structure of MmpL3 was manually built using COOT (Emsley and Cowtan, 2004) . After several cycles of iterative manual building in COOT and refinement in PHENIX, the structure had the final R work /R free values of 0.223/0.249, respectively. The final density of the fused lysozyme was unambiguous ( Figure S1F ). The structures of the complexes with SQ109, AU1235, ICA38 and rimonabant were solved by molecular replacement, with the apo-structure as the search model using the program PHASER (McCoy et al., 2007) . Refinement was carried out in PHENIX allowing the XYZ coordinates to vary in real-space. Each atom was refined to have an individual isotropic B-factor. The rigid body motion of the protein was fitted according to TLS parameters. Data collection and structure refinement statistics are summarized in Table S1 .
BLUE NATIVE PAGE
In order to determine the native oligomerization state of the full-length MmpL3 in solution, we utilized the Blue Native PAGE technique (Wittig et al., 2006) . The purified MmpL3 protein sample was mixed with 10 3 loading buffer (0.1% (w/v) Ponceau S, 50% (w/v) glycerol) and subjected to 4%-16% Blue Native PAGE mini gel (1.5 3 8.3 3 7.3mm) for electrophoresis at 4 C. After the native gel electrophoresis was conducted at 100 V for 10 min, cathode buffer B (50 mM Tricine, 7.5 mM imidazole, 0.02% (w/v) Coomassie brilliant blue G-250) was changed to cathode buffer B/10 (50 mM Tricine, 7.5 mM imidazole, 0.002% (w/v) Coomassie brilliant blue G-250) and the run continued at 150 V for 1.5 h. All buffers and procedures were based on a previously published Blue Native PAGE protocol (Wittig et al., 2006) .
Small-angle X-ray scattering (SAXS)
Small-angle X-ray scattering (SAXS) experiments were performed at beamline BL19U2 at Shanghai Synchrotron Radiation Facility (SSRF). The wavelength, l, of X-ray radiation was set as 1.033 Å . Scattered X-ray intensities were collected using a Pilatus 1M detector (DECTRIS Ltd). The sample-to-detector distance was set such that the detecting range of momentum transfer [q = 4p sinq/l, where 2q is the scattering angle] of SAXS experiments was 0.01-0.45Å -1 . To reduce the radiation damage, a flow cell made of a cylindrical quartz capillary with a diameter of 1.5 mm and a wall of 10 mm was used. SAXS data were collected as 20 3 1 s exposures and scattering profiles for the 20 passes were compared at 10 C using 60 mL sample in 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10% (v/v) glycerol and 0.02% (w/v) DDM. In considering the stability for transmembrane structure, the sample was concentrated to 3 mg mL -1 . For comparison, the same measurement was taken using 5 mg mL -1 bovine serum albumin (BSA) as a standard. The 2-D scattering images were converted to 1-D SAXS curves through azimuthally averaging after solid angle correction and then normalizing with the intensity of the transmitted X-ray beam, using the software package BioXTAS RAW (Nielsen et al., 2009) . Background scattering was subtracted using PRIMUS in ATSAS software package (Petoukhov et al., 2012) . Linear Guinier plots in the Guinier region (q*R g <1.3) were confirmed in all experimental groups (calculated R g value was shown in Table S2 ). Pair distance distribution functions of the particles P(r) and the maximum sizes D max were computed using GNOM (Svergun, 1992) and molecular weights were estimated by comparison of the extrapolated forward scattering I(0) of the samples obtained using Guinier analysis by AUTORG (Petoukhov et al., 2007) with that of a BSA standard (Sigma-Aldrich). The molecular weight was also calculated based on the porod volume (V p ) and the excluded volume of molecule (V dammif ) by introducing an experience factor 1.6. The molecular comparison between theoretical and SAXS estimated parameters were listed in Table S2 .
Microscale thermophoresis assay
Binding affinities of SQ109, AU1235, ICA38 and rimonabant with the purified wild-type and MmpL3 mutants were measured by using the Monolith NT.115 (Nanotemper Technologies). The proteins were fluorescently labeled according to the manufacturer's procedure and kept in the MST buffer (20 mM HEPES, pH 7.0, 150 mM NaCl, 0.02% (w/v) DDM) at a concentration of 200 nM. Next, the RED fluorescent dye NT-647 was added, mixed and incubated for 30 min at 25 C in the dark. For each assay, the labeled protein was mixed with the same volume of unlabeled inhibitor (SQ109, AU1235, ICA38 or rimonabant) at 16 different serially diluted concentrations at room temperature. The samples were then loaded into premium capillaries (NanoTemper Technologies) and measured at 25 C by using 40% LED power and medium MST power. Each assay was repeated three times. Data analyses were performed using MO. Affinity Analysis v.2.2.4 software. There is 95% confidence, that the K d value is within the given range. All figures were made by GraphPad Prism 5.0.
MmpL3 overexpression and drug susceptibility testing
To confirm MmpL3 as the drug target of SQ109 and rimonabant, we overexpressed the endogenous mmpL3 gene in M. smegmatis and tested drug susceptibility as described previously (Shi et al., 2011) . The mmpL3 gene (MSMEG_0250) and its own promoter were ligated to the pOLYG plasmid (Gaora, 1998) and electroporated into M. smegmatis strain mc 2 155 cells. Different strains (pOLYG-mmpL3 and pOLYG vector as control) were printed at a density of $10 5 CFU mL -1 on LB agar plates supplemented with drugs with different concentrations. The experiments were performed in triplicate to assess the effects of MmpL3 overexpression on SQ109 and rimonabant susceptibility.
Molecular docking
Each compound was docked to the transmembrane inner cavities of all crystal structures of MmpL3 using Schrodinger Glide software in SP mode with default parameters (Friesner et al., 2004) . For each compound, the docking model with the lowest binding affinity score was selected for further analysis. Considering the receptor flexibility, the Rosetta-Ligand application (Davis and Baker, 2009; Fleishman et al., 2011; Lemmon and Meiler, 2012) was applied to generate accurate molecular docking models. Starting from each selected Glide docking model, each compound was re-docked to its target protein. Its center of mass was constrained to move within a 1 nm diameter sphere, where it was allowed to move freely during the docking process. Side-chains in the binding site were repacked using a rotamer library. The docking model with the lowest binding energy was selected for analysis.
Supplemental Discussion
There has been debate as to whether MmpL3 causes resistance through drug efflux or not. Our structural models support the latter conclusion. In the structure of AcrB (a classic drug efflux pump in RND superfamily), the typical proximal substrate pocket and distal substrate pocket are located in the pore domain for transport of antibiotics/drugs (Murakami et al., 2006; Nakashima et al., 2011) . However, in the structure of MmpL3, the inhibitor binding site revealed in MmpL3 is located inside the proton-translocation pathway within the transmembrane domain, which is proposed to generate the proton motive force for RND superfamily. Thus, it is unlikely that in addition to exporting TMM, MmpL3 can also act as a drug efflux pump. There is also controversy as to whether the inhibitor, THPP, targets MmpL3, although EchA6 has been identified as one target (Cox et al., 2016) . There are four mutations (A249P, F644C, A677V and V713M) that confer THPP resistance (Remuiñ á n et al., 2013), which can be mapped onto our structural model ( Figure S7E ). It shows that they are all located in the transmembrane domain, either within or close to the inhibitor binding pocket, suggesting that THPP could target MmpL3. In addition, THPP displays inhibitory activity against a broad spectrum of pathogens that are devoid of mycolic acids (Ballell et al., 2013) , which implies it might have multiple targets.
QUANTIFICATION AND STATISTICAL ANALYSIS
The dissociation constants (K d ) in Microscale thermophoresis (MST) experiments were calculated using MO. Affinity Analysis v.2.2.4 software as Mean ± SEM from three independent experiments with a single site-specific binding model.
DATA AND SOFTWARE AVAILABILITY
The PDB accession codes for apo-MmpL3, MmpL3-SQ109, MmpL3-AU1235, MmpL3-ICA38 and MmpL3-rimonabant are PDB: 6AJF, 6AJG, 6AJH, 6AJJ and 6AJI, respectively. (legend continued on next page)
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